Amgen gets a full approval for Imdelltra
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
Tempest’s third makeover
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Zymeworks moves to repeat the Ziihera trick
The company adds royalty aggregation to its R&D business.
Ziihera bags a gastric win
But Enhertu is coming.
Nuvalent presses ahead in ALK
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
Sutro goes back to work
The restructured biotech’s new lead project enters phase 1.
For $3bn J&J holds on to Halda
The private biotech adds another asset to J&J’s prostate cancer pipeline.
Amgen goes pivotal with subcutaneous Blincyto
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
